Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Cancer Metastatic × Tamoxifen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 88 Carcinoma, Intraductal, Noninfiltrating 11 Breast Carcinoma In Situ 9 Ovarian Neoplasms 6 Neoplasm Metastasis 6 Breast Neoplasms, Male 6 Neoplasms 5 Glioblastoma 4 Central Nervous System Neoplasms 4 Inflammatory Breast Neoplasms 3 Gliosarcoma 3 Urinary Bladder Neoplasms 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Glioma 2 Fallopian Tube Neoplasms 2 Breast Cancer Female 2 Brain Neoplasms 2 Astrocytoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Risk Reduction Behavior 1 Recurrence 1 Premenopausal Breast Cancer 1 Oligodendroglioma 1 Non Metastatic Breast Cancer 1 Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer 1 Neuroendocrine Tumors 1 Multiple Endocrine Neoplasia Type 1 1

Interventions

Fulvestrant 5 Letrozole 3 ribociclib 2 exemestane 2 dalpiciclib 2 apatinib 2 Gemcitabine 2 Capecitabine 2 Anastrozole 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 palbociclib 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Vinorelbine 1 Trastuzumab 1 Tamoxifen 1 Paclitaxel 1 Liposomes 1 Irinotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04059484 2026-02-24

AMEERA-3

Sanofi

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡